Leerink Partners analyst David Risinger has maintained their neutral stance on AMGN stock, giving a Hold rating on August 26.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David Risinger has given his Hold rating due to a combination of factors influencing Amgen’s future prospects. The recent approval for Repatha’s expanded label is expected to enhance its market penetration, particularly in the primary prevention space for cardiovascular events. Despite this positive development, the current market penetration remains low, and the immediate opportunity lies more in increasing treatment urgency rather than expanding the patient base.
While the label expansion supports strong growth potential for Repatha in the coming years, there are significant long-term risks that temper enthusiasm. These include potential price controls under Medicare Part D starting in 2029 and the looming threat of biosimilar competition following the expiration of Repatha’s patents. Although certain patents may provide protection until 2032-2033, these factors contribute to a cautious outlook, justifying the Hold rating on Amgen’s stock.
Risinger covers the Healthcare sector, focusing on stocks such as Regeneron, Eli Lilly & Co, and Amgen. According to TipRanks, Risinger has an average return of 9.5% and a 55.89% success rate on recommended stocks.
In another report released on August 26, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $317.00 price target.